Difference between revisions of "Cabozantinib (Cometriq)"
Jump to navigation
Jump to search
m (Text replacement - "[[File:" to "[[:File:") |
m |
||
| Line 12: | Line 12: | ||
*[[Renal cell carcinoma]] | *[[Renal cell carcinoma]] | ||
**[[Papillary renal cell carcinoma]] | **[[Papillary renal cell carcinoma]] | ||
| − | *[[ | + | *[[Thyroid cancer]] |
| + | **[[Differentiated thyroid cancer]] | ||
| + | **[[Medullary thyroid cancer]] | ||
==Patient drug information== | ==Patient drug information== | ||
| Line 23: | Line 25: | ||
===[[Hepatocellular carcinoma]]=== | ===[[Hepatocellular carcinoma]]=== | ||
*1/14/2019: Approved for patients with [[Hepatocellular carcinoma|hepatocellular carcinoma (HCC)]] who have been previously treated with [[Sorafenib (Nexavar)|sorafenib]]. ''(New disease entity; based on CELESTIAL)'' | *1/14/2019: Approved for patients with [[Hepatocellular carcinoma|hepatocellular carcinoma (HCC)]] who have been previously treated with [[Sorafenib (Nexavar)|sorafenib]]. ''(New disease entity; based on CELESTIAL)'' | ||
| − | ===[[ | + | ===[[Medullary thyroid cancer]]=== |
| − | *11/29/2012: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm330213.htm Initial approval] (as Cometriq) for treatment of progressive metastatic [[ | + | *11/29/2012: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm330213.htm Initial approval] (as Cometriq) for treatment of progressive metastatic [[Medullary_thyroid_cancer | medullary thyroid cancer (MTC)]]. ''(Based on EXAM)'' |
===[[Renal cell carcinoma]]=== | ===[[Renal cell carcinoma]]=== | ||
*4/25/2016: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm497483.htm Approved] (as Cabometyx) for the treatment of advanced [[Renal_cell_carcinoma|renal cell carcinoma]] in patients who have received prior [[:Category:VEGFR_inhibitors|anti-angiogenic therapy]]. ''(New disease entity; based on METEOR)'' | *4/25/2016: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm497483.htm Approved] (as Cabometyx) for the treatment of advanced [[Renal_cell_carcinoma|renal cell carcinoma]] in patients who have received prior [[:Category:VEGFR_inhibitors|anti-angiogenic therapy]]. ''(New disease entity; based on METEOR)'' | ||
| Line 39: | Line 41: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| − | |||
[[Category:AXL inhibitors]] | [[Category:AXL inhibitors]] | ||
| Line 56: | Line 57: | ||
[[Category:Prostate cancer medications]] | [[Category:Prostate cancer medications]] | ||
[[Category:Renal_cell_carcinoma medications]] | [[Category:Renal_cell_carcinoma medications]] | ||
| − | [[Category: | + | [[Category:Differentiated thyroid cancer medications]] |
| + | [[Category:Medullary thyroid cancer medications]] | ||
[[Category:FDA approved in 2012]] | [[Category:FDA approved in 2012]] | ||
Revision as of 18:15, 21 September 2021
General information
Class/mechanism: Tyrosine kinase inhibitor; inhibits RET, MET/c-Met, VEGFR-1, VEGFR-2, VEGFR-3, KIT, TRKB, FLT-3, AXL, and TIE-2.[1][2][3][4][5][6]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1][4]
Diseases for which it is used
- Hepatocellular carcinoma
- Non-small cell lung cancer
- Prostate cancer
- Renal cell carcinoma
- Thyroid cancer
Patient drug information
- Cabozantinib (Cometriq) package insert pages 20-24[1] (the numbering for the PDF is off, so in some PDF viewers, the patient information is on pages 27-31)
- Cabozantinib (Cabometyx) package insert[4]
- Cabozantinib (Cometriq) patient drug information (Chemocare)[7]
- Cabozantinib (Cometriq) patient drug information (UpToDate)[8]
History of changes in FDA indication
Hepatocellular carcinoma
- 1/14/2019: Approved for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. (New disease entity; based on CELESTIAL)
Medullary thyroid cancer
- 11/29/2012: Initial approval (as Cometriq) for treatment of progressive metastatic medullary thyroid cancer (MTC). (Based on EXAM)
Renal cell carcinoma
- 4/25/2016: Approved (as Cabometyx) for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy. (New disease entity; based on METEOR)
- 12/19/2017: Granted FDA regular approval for treatment of patients with advanced renal cell carcinoma (RCC). (Converted to regular approval; no longer requires prior treatment; based on CABOSUN)
Also known as
Note: Cometriq is the brand name for cabozantinib's medullary thyroid cancer indication. Cabometyx is the brand name for cabozantinib's renal cell carcinoma indication.
- Code names: XL184, XL-184
- Brand names: Cabometyx, Caboxen, Cabozanib, Cabozanix, Cometriq, Lucicaboz
References
- ↑ 1.0 1.1 1.2 Cabozantinib (Cometriq) package insert
- ↑ Cabozantinib (Cometriq) package insert (locally hosted backup)
- ↑ Cometriq manufacturer's website
- ↑ 4.0 4.1 4.2 Cabozantinib (Cabometyx) package insert
- ↑ Cabozantinib (Cabometyx) package insert (locally hosted backup)
- ↑ Cabometyx manufacturer's website
- ↑ Cabozantinib (Cometriq) patient drug information (Chemocare)
- ↑ Cabozantinib (Cometriq) patient drug information (UpToDate)
Categories:
- Drugs
- Oral medications
- AXL inhibitors
- FLT3 inhibitors
- KIT inhibitors
- MET inhibitors
- RET inhibitors
- ROS1 inhibitors
- TEK inhibitors
- TRK inhibitors
- VEGFR inhibitors
- Hepatocellular carcinoma medications
- Non-small cell lung cancer medications
- Papillary renal cell carcinoma medications
- Prostate cancer medications
- Renal cell carcinoma medications
- Differentiated thyroid cancer medications
- Medullary thyroid cancer medications
- FDA approved in 2012